Muscle precursor cell (myoblasts) transplantation is considered as a potential approach to restore dystrophin expression in Duchenne muscular dystrophy (DMD) patients. The study purpose was to verify the implication of hypoxia in the myoblast death observed after their transplantation and also to evaluate the potential beneficial effects of vascular endothelial growth factor (VEGF) overexpression on myoblast engraftment in a murine model. Pimonidazole hydrochloride (hypoxyprobe-1) was used to mark selectively myoblasts to evaluate their hypoxia in vivo. In vitro, hypoxia was induced by culturing human myoblasts in hypoxic environment. In vitro effects of VEGF 165 on survival of human cells was assessed by Hoescht-PI labeling. Tibialis anterior (TA) female mouse muscles were electroporated with a plasmid containing the VEGF 165 or with an empty vector. Circulating VEGF concentration was assessed by ELISA. After 2 weeks of electroporation, severe combined immunodeficient (SCID) mice were transplanted with 800 000 human male myoblasts labeled with radioactive thymidine. Mouse muscles were harvested 2 and 4 days later and myoblast survival and proliferation were evaluated by scintigraphy and Y chromosome quantitative PCR. The long-term graft success was evaluated using g-radiograph imaging and by counting the dystrophin positive muscle fibers. Hypoxyprobe labeling has shown that most of the transplanted myoblasts were hypoxic. The transplantation of radioactive male myoblasts in female mice electroporated with the VEGF 165 plasmid demonstrated that VEGF reduced their death by 10% but did not improve their proliferation. VEGF 165 enhanced human myoblast survival in vitro under hypoxic conditions. Electroporation of TA muscles of SCID mouse with the vector coding for VEGF 165 promoted angiogenesis and improved by 1.5-fold the success of myoblast transplantation in comparison with the control mice that were electroporated with the empty vector. These results indicate that hypoxia is partially responsible for the death of the transplanted myoblasts. VEGF can be used to improve myoblast survival and the graft success.
Introduction
Transplantation of muscle precursor cells (MPCs) or myoblasts is considered as a potential approach to repair damaged skeletal muscles in a number of recessive muscular dystrophies, in particular, Duchenne muscular dystrophy (DMD) . 1 This approach is however limited by the death of the majority of the cells within 4 days following their injection. 2, 3 Therefore, it is presently necessary to transplant a large number of MPCs (30 millions per cm 3 ) in pathologic muscles. 4 The massive and early death of transplanted myoblasts may be due to several mechanisms including anoikis, inflammatory response and hypoxia.
Hypoxia is a physiopathological state resulting from the blockade and/or reduction of the oxygen supply in a given region of the body. In the context of cellular transplantation, the phenomenon could constitute an important obstacle to the myoblast viability. Indeed, during their transplantation, myoblasts are injected along trajectories but cell pockets are formed at the end of these as well as along these trajectories. 5 The cells in the center of these pockets may have a reduced oxygen supply. Moreover, the myoblast injection procedure could damage the blood vessels present in the injected zone restricting the blood supply and therefore oxygen supply to the transplanted cells. In a physiological context, vascular endothelial growth factor (VEGF) is secreted by endothelial cells to promote neo-vascularization. VEGF is a 27 kDa homodimeric signaling glycoprotein mainly secreted by endothelial cells and involved in both vasculogenesis and angiogenesis. VEGF acts on endothelial progenitor cells by promoting their proliferation, migration and survival. 6 It is also overexpressed and secreted by some malignant cells. VEGF production is also induced in cells that are not receiving enough oxygen. When a cell is deficient in oxygen, it produces the hypoxia inducible factor (HIF) that stimulates in turn the release of VEGF. Circulating VEGF then binds to VEGF receptors on endothelial cells, triggering a tyrosine kinase pathway leading to angiogenesis. 7 Recent data demonstrated that VEGF transient overexpression prolongs islet survival after transplantation. 8 The purposes of this study were to verify whether ischemia is implicated in the early death of myoblasts transplanted in severe combined immunodeficient (SCID) mouse TA muscles and to evaluate the effect of VEGF overexpression on survival of cells and graft success.
Results
Transplanted myoblasts become hypoxic indicating that the injection procedure restricts oxygen supply to the cells A total of 500 000 human myoblasts were injected into TA muscles of 24 SCID mice. Muscles were harvested either at the time of injection (T0), 6 h (T6), 12 h (T12) or 24 h (T24) later. Using the Hypoxyprobe-1 labeling kit, we have demonstrated that transplanted myoblast became hypoxic during the first 6 h following their transplantation ( Figure 1) . Indeed, 7.23% of the injected cells were hypoxic at T0. At T6, T12 and T24, the proportion of hypoxic myoblasts was, respectively, 89.6, 73.1 and 46.8%. Using nicotinamide adenine dinucleotide reduced tetrazolium reductase (NADH-TR) labeling, we have shown that inner part of the cell pocket unlabeled with hypoxyprobe at T24 contained dead cells. This explains the reduction in the percentages of hypoxic cells (that is, hypoxyprobe positive) observed at 12 and 24 h compared with the 6 h results.
Human myoblast express VEGFR-2
The presence of the VEGF receptor (VEGFR)-2 on human myoblasts was demonstrated by immunocytochemistry ( Figure 2 ). Labeling with VEGFR-2 antibody appears to be cytoplasmic because it is an immunocytochemistry reaction performed on cells in culture. Since cells are tridimensional entities and the VEGF receptor is located in the cell membrane, the labeling appears to be also located in the cytoplasm while it is only present on cell plasma membrane.
VEGF 165 overexpression by human myoblasts enhanced their survival in vitro
Human myoblasts infected with the pBabe-VEGFIres-puro retrovirus or with the empty pBabe-Ires-puro vector were plated in 6-well plates at 75% of confluence VEGF enhances myoblast survival in vitro and in vivo M Bouchentouf et al in serum-free medium in oxygenated or hypoxic atmosphere for 24 h. Cells were then harvested and the percentage of apoptotic cells in each condition was evaluated by fluorescence-activated cell sorting (FACS) following the Hoescht-PI labeling technique. Results in Figure 3a shows that myoblasts infected with the pBabe-VEGF-Puro vector were 1.9-fold more resistant to hypoxia-induced apoptosis than control myoblasts infected with the empty vector. Some myoblasts were also cultured in hypoxic conditions but in presence of conditioned medium (CM) harvested from myoblasts secreting the VEGF 165 . These myoblasts treated with CM were also resistant to hypoxia in vitro. Indeed, there was 1.4-fold more living myoblasts in comparison with control cells without any treatment. VEGF 165 concentration in CM was dosed by enzyme-linked immunosorbant assay (ELISA). VEGF 165 concentration was 684 pg ml À1 in medium harvested from myoblasts infected with pBabe-VEGF-Ires-puro retrovirus while basal level of VEGF 165 in medium harvested from cells infected with the empty pBabe-Ires-puro retrovirus was 98 pg ml À1 (Figure 3b ).
Electroporation of SCID mouse TA muscles with the pCEP4-VEGF vector promoted VEGF 165 production SCID mouse TA muscles were electroporated with the pCEP4-VEGF or with the pCEP4 empty vector. Blood samples were harvested at the time of electroporation and 11, 18, 22, 27 and 29 days later. Circulating human VEGF was evaluated by ELISA in the sera. In mice electroporated with pCEP4-VEGF vector, the VEGF 165 serum concentration increased progressively starting at the time of electroporation and stabilized at day 27 following electroporation at a concentration of 295 pg ml
À1
. In mice electroporated with the pCEP4 empty vector there was no detectable human VEGF (Figure 4 ). ELISA tests for mouse VEGF were also done to evaluate its concentration in sera harvested from mice electroporated with the pCEP4-VEGF or the pCEP4 empty vector. Electroporation did not change the concentration of circulating mouse VEGF, which varied between 45 and 60 pg ml À1 (data not shown).
Electroporation of SCID mouse TA muscles with the pCEP4-VEGF vector promoted angiogenesis TA muscles of SCID mice were electroporated with the pCEP4-VEGF or with the pCEP4 empty vector. Muscles were harvested at the time of electroporation (T0), 3 days (T72) and 5 days (T120) later. Muscles were cryostat sectioned and labeled with an anti-CD144 antibody ( Figure 5 ). To quantify the CD144 labeling on the sections from the fluorescent signals, photos of muscle sections Electroporation of SCID mouse TA muscles with vector coding for the VEGF 165 reduced transplanted myoblast death but had no effect on their proliferation
To verify whether VEGF can enhance cell survival in vivo, some mice were electroporated with the pCEP4-VEGF vector and others were electroporated with pCEP4 empty vector. After 18 days of the electroporation, 5 Â 10 5 human male myoblasts radiolabeled with radioactive thymidine also carrying the hNIS reporter gene were injected into eight sites of TA muscles. Muscles were then removed at T0, T0+48 h and T0+96 h, and the amount of radiolabel was measured in DNA extracts of each TA muscle. The results in Figure 6a demonstrate that 200 pg ml À1 of VEGF in the serum improved significantly by 1.4-fold the survival of injected cells 4 days after the transplantation. Indeed there was 17% living cell remaining in the control group of mice electroporated with empty pCEP4 vector whereas 24% of the cells were still alive in the group of mice electroporated with pCEP4-VEGF vector.
To evaluate the effect of circulating VEGF 165 overexpression on human myoblast proliferation in vivo and Figure 6c demonstrate that VEGF had no effect on myoblast proliferation. Indeed, the proliferation index was not different between mice electroporated with the pCEP4-VEGF or with the pCEP4 empty vector.
g-scintigraphies were also performed on electroporated mice to evaluate the engraftement (survival and/or proliferation) of human myoblasts labeled with in culture with a lentivirus coding for hNIS and with a lentivirus coding for eGFP. Before 3 h of the scintigraphy, the mice received an intraperitoneal injection of 300 mCi Na 99 mTcO 4 . They were then anesthetized with a 0.1 ml per 10 g mixture of 15 mg ml À1 ketamine and 1 mg ml
xylazine and then exposed to the g-camera. The whole body radioactivity was taken as reference to compare the muscle relative intensity. Images in Figure 7a show the Na In each panel, a representative mouse radiograph is illustrated. Statistics for image corresponding to Na 99 mTcO 4 uptake is shown on the right of g-radiographs. The results of g-scintigraphies are shown in Figure 7b . After 3 days of myoblast transplantation there was no difference in the amount of Na 99 mTcO 4 uptake between the TA muscle of mouse electroporated with the pCEP4-VEGF or with the pCEP4 empty vector. However, 1 week after human myoblast transplantation, the amount of Na 99 mTcO 4 uptake was reduced from 0.035 to 0.014% and from 0.037 to 0.011%, respectively, in mice electroporated with pCEP4-VEGF and mice electroporated with pCEP4 empty vector. Myoblasts proliferated slightly in both groups during 2 following weeks. At 3 weeks posttransplantation, the amount of Na 99 mTcO 4 uptake was significantly higher (1.3-fold) in mice electroporated with pCEP4-VEGF vector in comparison with the mice electroporated with the empty plasmid.
VEGF 165 expression enhanced myoblast graft success
To verify whether the VEGF 165 expression enhanced myoblast graft success, 5 Â 10 5 human myoblasts infected with eGFP and hNIS lentiviruses were injected into five SCID mouse TA muscles. After 4 weeks of their transplantation, muscles were harvested and graft success was evaluated by counting the number of eGFP positive fibers. VEGF 165 expression enhanced graft success by 1.3-fold. Indeed, there were 132 eGFP positive fibers in the transplanted muscles also electroporated with the pCEP4-VEGF vector in comparison with the mouse electroporated with the pCEP4 empty vector where in average 99 fibers were eGFP positive ( Figure 8 ).
Discussion
MPC transplantation is limited by the massive and early death of the major part of transplanted myoblasts. The proportion of myoblasts that died following transplantation was quantified by several groups. Huard et al. 9 transplanted genetically modified myoblast expressing the luciferase in mdx and normal mice muscles. They reported an important decrease in the expression of the luciferase indicating a major loss of cells 48 h after their transplantation. The team of Dr Grounds reported a loss of 90% of myoblast transplanted into mdx and C57B1/10Sn VEGF enhances myoblast survival in vitro and in vivo M Bouchentouf et al mice during the first week following their injection. 10 The approach used by Fan et al. to quantify the death of injected cells consisted in transplanting myoblasts obtained from C57B1/10Sn male mice in mdx and C57B1/10Sn female mice. Analysis of the Y chromosome of DNA extracted from injected muscles showed a decrease in myoblast number beginning 2 days posttransplant and continuing for 7 days. The injection of myoblasts carrying gene of b-galactosidase allowed to estimate a loss from 70 to 80% during the 3 days post-grafts. 11, 12 By labeling myoblasts with radioactive thymidine, Beauchamps et al. 13 estimated to 99% the proportion of myoblasts that die 4 days following their transplantation. As indicated in a recent review article on myoblast death published by our group, these differences are explained by the fact (1) that methods used to quantify the death of the transplanted myoblasts were different, (2) that the authors used different references to establish 100% of living cells and finally (3) that the transplanted cells were also different. 14 Myoblast early and massive death may be caused in part by the reduction of the arterial blood supply within the injection zone generally due to damage, constriction or blocking of blood vessels contributing to hypoxia. Hypoxia may also be caused by the transplantation procedure consisting in injecting myoblasts to form cell pockets. The aims of our study were to evaluate the implication of hypoxia in the early death of transplanted myoblasts and to verify whether the VEGF 165 could improve their survival and/or proliferation.
We first used pimonidazole hydrochloride (hypoxyprobe-1) labeling to evaluate hypoxia within transplanted 
Our results show that the injections formed cell pockets that were hypoxic starting 6 h following the transplantation into SCID mouse TA muscles. A total of 70% of the transplanted cells were on average hypoxic during the first 24 h following their injection. NADH-TR labeling was also performed on myoblasts 24 h following their injection to identify viable and dead cells. 15 The NADH-TR labeling permits to detect mitochondrial NADH dehydrogenase activity, which indicates the presence or absence of cellular oxidative activity. A negative myoblast NADH-TR staining indicates mitochondrial alteration and cell death. The NADH-TR immunoreaction showed that a central area of the injection myoblast pocket contained non-viable cells surrounded by a peripheral zone containing living myoblasts. This result suggests that hypoxic cells on the outside of the pockets were still alive. However, those located in the center were already dead. Only few groups have focused on hypoxia-induced death of myoblasts. It has been shown that myoblasts transplanted into the heart die by apoptosis or necrosis due to hypoxia. 16, 17 In other cell types, recent data suggested that 24 h of hypoxia of pancreatic cells led to central necrosis combined with apoptotic features (nuclear pyknosis and DNA fragmentation). Moreover, during the hypoxic treatment, ultrastructural analysis demonstrated a gradual transition from an apoptotic to a necrotic morphology particularly pronounced in central areas of large islets. 18 We have also demonstrated that the VEGFR-2 is expressed in human myoblasts. Under normoxic conditions, HIF-1 (a) is continuously degraded by endogenous ligases (prolyl-hydroxydase) that use oxygen as a cofactor. Under hypoxic conditions, prolyl-hydroxydase is inhibited and HIF-1a is expressed. HIF-1a expression induces upregulation of several genes including the VEGF. 19 The effect of VEGF on human myoblast survival was thus evaluated in vitro by infecting the cells with a retrovirus coding for VEGF 165 . The effect of VEGF on myoblast survival was also investigated in vivo by transplanting them in SCID mouse TA muscles electroporated with a plasmid coding for VEGF 165 . We have reported that in mice electroporated with pCEP4-VEGF vector, the VEGF 165 serum concentration increased to achieve a serum concentration of 295 pg ml
À1
. Other groups overexpressed VEGF and they observed an increase in the concentration VEGF. Indeed, Jiang et al. 20 have shown that electroporation of rat muscle with a plasmid coding for VEGF increased its level in the plasma. Germani et al. 21 have shown in vitro that C2C12 cells infected with adenovirus coding for VEGF were more resistant to apoptosis and that VEGF concentration in growth medium was in average 600 pg ml
. We have shown that VEGF production reduced in vitro myoblast apoptosis-induced by hypoxia. These results suggest that VEGF protects directly human myoblasts from hypoxiainduced apoptosis via its receptor. It is already well established that VEGF 165 production promotes survival of melanoma cells through MAPK and PI3K signaling pathways and that melanoma growth and survival is mediated via a VEGF-dependent internal autocrine loop mechanism. 22 It has been reported that binding of VEGF 165 to VEGFR-2 of human vascular endothelial cells induces the phosporylation of PI3K that in turn activates the Akt protein kinase. Akt then repress caspase 9 and Bad, two pro-apoptotic proteins. VEGF also induces expression of the anti-apoptotic protein, Bcl-2, which upregulates the X-chromosome-linked inhibitor of apoptosis proteins (XIAP) inhibiting activation of upstream caspases. 23 Moreover, VEGFR-2 activation by VEGF 165 has been reported to exert profound effects on endothelial cell survival via a V b 5 integrins. 24 Stimulation of a V b 5 integrins by binding to vitronectin has been reported to enhance cell survival by promoting Akt protein-kinase and Bcl-2 anti-apoptotic protein expression. 25 In addition, it has been reported that angiogenic pretreatment of infarcted myocardium may improve implanted cell survival and consequently myocardial function. 26 Indeed, that research group has demonstrated that administration of adenovirus coding for VEGF improved survival of myoblasts transplanted into the heart and that left ventricular ejection fraction was also enhanced. Previous studies have demonstrated that VEGF expression is modulated by hypoxia and ischemia 27 and that its expression modulates angiogenesis. 28 Cell and gene based therapies were previously used to improve blood vessel density in and around the rat and swine infracted myocardium. 29, 30 Our in vivo observations show that VEGF reduced myoblast hypoxia and also promoted angiogenesis (Figures 3 and 5) . VEGF enhanced transplanted human myoblast survival and their engraftment. Indeed, elevated levels of human VEGF enhanced by 1.4-fold 4 days following their transplantation. Moreover, the graft success was 1.3-fold higher in the mice electroporated with the plasmid coding for the VEGF 165 than in control mice electroporated with the empty vector ( Figure 8 ). The final yield increase due to VEGF was small and VEGF treatment may not lead to clinically relevant effect. The effect of VEGF can be explained by the fact that hypoxia participates partially to myoblast death and that other factors are also responsible of the VEGF enhances myoblast survival in vitro and in vivo M Bouchentouf et al early and massive myoblast death. These factors include inflammatory reaction and anoikis as shown by our group. 31, 32 Thus, induction of VEGF expression should be used, however, for cellular transplantation in combination with other treatments aimed at blocking other factors responsible of myoblast death. The observed improvement of myoblast survival and engraftment could be induced by: (1) a direct effect of VEGF on the transplanted cells via VEGFR-2 as for endothelial cells 33 and (2) an indirect effect mediated by endothelial mature and progenitor cells that promote damaged vessel regeneration and repair, 34 leading to a better vascularization and oxygenation of the surrounding muscular tissue. Several studies reported that neo-vascularization is an early event that begins 3-4 days following vessel damage and continues during 2 weeks. Indeed, endothelial progenitor cells first proliferate and migrate to the site of injury then they fuse to form new vessels. It was however demonstrated that neo-vascularization was obtained as soon as 1 day after surgery in rabbits treated with adenovirus coding for VEGF. 35 Moreover, it has been shown that the development of new vessels induced by VEGF overexpression allowed the restoration of the blood flow within the treated tissue 1 day following electroporation. 36 However, VEGF production had no effect on transplanted myoblast proliferation in opposition to a variety of endothelial cells 37 on which VEGF promotes proliferation.
All these data taken together indicate that hypoxia is involved in the death of transplanted myoblasts and that the VEGF treatment is a method to improve their survival. These results are consistent with a recent publication that showed that VEGF reduced myogenic cell death in vitro and promoted the growth of myogenic fibers. 38 In a recent publication, Skuk 39 have shown that the amount of cells that die following their transplantation into monkey skeletal muscle decreased when the size of cell pocket is reduced. However, it is currently difficult to control with precision the volume of myoblasts injected along an injection trajectory. Our team is working on the development of an automatic injection device to control the injection pressure and the volume of myoblast injected. Exact mechanisms of myoblast survival improvement in presence of VEGF were not investigated in the present study. Further investigations will be necessary to identify the pathways implicated in the observed effects of VEGF on transplanted human myoblasts.
Materials and methods
This work was authorized and supervised by Laval University Animal Care Committee. Manipulations were conducted according to guidelines set by the Canadian Council of Animal Care.
Reagents
Fetal bovine serum (FBS), Dulbecco's modified Eagle's medium (DMEM), lipofectamine and penicillin/streptomycin were obtained from Invitrogen (Burlington, Ontario, Canada). The anti-VEGF polyclonal antibody was purchased from Abcam (Cambridge, UK). Hank's balanced salt solution (HBSS) and collagenase were purchased from Sigma Aldrich (St-Louis, MO, USA).
The LightCycler Fast Start DNA Master SYBRGreen was purchased from Roche (Indianapolis, IN, USA). The [methyl-14 C]-thymidine was purchased from PerkinElmer (Boston, MA, USA). QIAamp DNA extraction minikit was obtained from QIAGEN (Mississauga, Ontario, Canada). Hypoxyprobe-1 was purchased from Chemicon (Vic., Australia). Human VEGF ELISA kit was purchased from R&D Systems (Minneapolis, MN, USA) .
In vitro hypoxia induction
In order to determine the best concentration of oxygen to induce death due to hypoxia, we performed a dose-effect curve using five different oxygen concentrations (21, 10, 3, 1 and 0.5%). Our results showed that at 21% O 2 , all cells were alive and that there were low amounts of apoptotic myoblasts at 10% O 2 . The percentage of apoptotic cells increased at 3% O 2 and reached 55%. The number of apoptotic myoblasts was maximal at 1% O 2 and 0.5% O 2 (70 and 65%).
In vivo hypoxia detection
Hypoxia within transplanted human myogenic cells was detected using the Hypoxyprobe-1 kit following step-bystep manufacturer protocol. Briefly, the probe was injected to transplanted mice 30 min before they are killed (60 mg kg À1 body weight). Muscles were then harvested and prepared for immunohistochemistry against hypoxyprobe using the provided hypoxyprobe-1 monoclonal antibody.
Nicotinamide adenine dinucleotide reduced tetrazolium reductase labeling NADH-TR was prepared by mixing 10 mg of blue tetrazolium (Sigma, Oakville, Ontario, Canada) with 8 mg of NADH (Sigma) in 10 ml of phosphate-buffered saline (PBS). Histochemical reaction was performed by incubating muscle sections with NADH-TR at 37 1C for 15 min. NADH-TR labeling was used to distinguish between alive and dead cells within the injection zone.
Cell culture
Human myoblasts were obtained after enzymatic digestion of human muscle biopsies with collagenase (2%) in HBSS for 45 min at 37.5 1C. The cells were then cultured at 37 1C in a humidified atmosphere with 5% CO 2 in proliferation medium (DMEM-high glucose (HG)) supplemented with 20% FBS and 1% penicillin-streptomycin.
VEGF retroviral vector construction
pCEP4 vector containing the VEGF 165 gene sequence used during gene electro-transfer was provided by Dr Terrence M Yau. The VEGF 165 retrovirus vector construction was done by extracting the VEGF 165 sequence from pCEP4 using BamHI and BglII restriction enzymes. pBABE-Puro vector was digested with BamH1 and BglII restriction enzymes. pBABE and VEGF 165 were treated with Klenow (Roche) to produce blunt ends. VEGF 165 was then cloned in pBABE-Ires-Puro vector using T4 DNA ligase (Roche). Empty pBABE or empty pCEP4 vectors were used as controls in the experiments.
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VEGF 165 retrovirus production and human myoblast infection
The day before the transfection, six million PA317 cells were plated in 6-well plate (1 million per well) in DMEM-HG medium supplemented with 10% FBS. Cells were transfected with 4 mg of the pBABE retroviral plasmid encoding human VEGF 165 and a puromycinresistance gene or with the empty pBABE plasmid (control) using the Lipofectamine 2000 transfection reagent. PA317 transfection medium was then removed and a freshly prepared DMEM-HG medium containing 6 mg ml À1 of puromycin was added to the cells for 4 days. Puromycin-resistant cells were then harvested, plated in T 75 flasks and incubated to reach 70% of confluence. The medium containing the VEGF 165 encoding retrovirus and the control retrovirus were then harvested, frozen in liquid nitrogen, and stored at À80 1C. Human myoblasts were infected by adding the medium containing VEGF or empty retrovirus to cells for 24 h. Infected human myoblasts were then cultured in MCDB growth medium supplemented with 6 mg ml À1 of puromycin for 4 days.
In vitro cell death assay
Apoptosis was induced by culturing myoblasts in 6-well plates at 75% confluence in a serum-free medium 24 h in hypoxic environment (0.5%. O 2 ). Cells were then harvested, washed with HBSS and resuspended in 50 ml of PI (20 mg ml
À1
) for 30 min at 4 1C in the dark. The suspension was fixed with 25% ethanol solution for 5 min and 25 ml of Hoechst 33342 solution (112 mg ml À1 ) was then added for 1 h at 4 1C in the dark as described by Shah et al. 40 The labeling of the cells was determined by FACS.
pCEP4-VEGF 165 and empty vector electroporation
Nine SCID mice were injected IM with 40 mg of pCEP4-VEGF 165 plasmid resuspended in 40 ml of 0.9% sterile NaCl using a 30-gauge needle insulin syringe and nine other SCID mice were injected with 40 mg of pCEP4 empty plasmid resuspended in 40 ml of 0.9% sterile NaCl. Electroporation was performed using two stainless steel plate electrodes connected to a BTX ECM830 electroporator and placed on the injected muscles and eight square electric pulses of 20 ms length with 200 V cm À1 at 2 Hz.
Enzyme-linked immunosorbent assay
ELISA was performed on electroporated mouse sera and on conditioned media harvested from myoblasts infected with retrovirus coding for VEGF165 or empty retrovirus following the supplier protocol. Before ELISA, serum samples were stored at room temperature for 30 min before centrifugation for 15 min at 1000 g. Serum was then harvested and aliquots were stored at À20 1C until the assay.
Myoblast transplantation
A total of 5 weeks old SCID female mice were used as hosts for these experiments. Both TA of recipient mice were used for the implantation of 5 Â 10 5 human male myoblasts in each muscle. On the day of transplantation, the cells were detached using 0.125% trypsin and washed in HBSS. Pellets were obtained by centrifugation at 6500 r.p.m for 5 min. The skin was opened to expose the TA muscle, and the myoblast pellet, resuspended in 20 ml of HBSS, was slowly injected throughout the TA muscle. The mice were killed at various times after the transplantation and the injected TA muscles were removed.
CD144 immunohistochemistry
CD144 also called vascular endothelial cadherin (VEcadherin) and cadherin-5 is a marker specific of endothelial cells. CD144 seems to play an important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with a-catenin forming a link to the cytoskeleton. 41 Endothelial cells were labeled using anti-mouse CD144. Cryostat sections were first fixed with 95% ethanol during 30 min. The muscle sections were washed three times with PBS. The nonspecific binding sites were then blocked with FCS (10%) in PBS for 1 h. The sections were then incubated for 1 h with the anti-CD144 antibody (1/100) followed by a goat antirabbit immunoglobulin G conjugated with Alexa 488 (1/100, 1 h; Molecular Probes, Montreal, Quebec, Canada). CD144 staining was observed using a fluorescent microscope.
VEGFR-2 and desmin immunocytochemistry
A total of 10 000 human myoblasts were plated in a 24-well plate. They were first fixed with 95% ethanol and washed three times with PBS. Cells were then incubated with an anti-VEGFR-2 (1:2500) or with an anti-desmin antibody for 1 h. Slides were then washed three times with PBS and incubated with secondary antibodies: ALEXA 546 anti-mouse (1:300) for desmin and ALEXA 488 anti-rabbit 1:300 for VEGFR-2 under moderate agitation. VEGFR-2 and desmin stainings were observed using a fluorescent microscope.
Hematoxyline-eosine labeling
Muscle sections were washed with distilled water then stained with hematoxylin and rinsed again in running tap water. Muscle sections were then washed with 0.3% alcohol and rinsed again in running tap water. Slides were stained with eosine for 2 min and then dehydrated and mounted for observation.
DNA extraction from muscle tissue DNA was extracted from transplanted tibialis anterior (TA) muscles using the QIAamp DNA mini-kit according to the manufacturer protocol. Briefly, muscles were minced and incubated with 20 ml of proteinase K in ATL buffer overnight at 56 1C. Digested muscles were then mixed with 200 ml of AL buffer and 200 ml of 100% ethanol and then applied to the QIAamp spin column. DNA was finally harvested in distilled water following two rounds of centrifugation at 6000 g and 13 000 g with AW1 and AW2 buffers, respectively.
In vivo cell death assay
To quantify in vivo cell mortality, myoblasts were radiolabeled by culturing them 24 h in growth medium containing 0.25 mCi ml
À1
[methyl- 
Production of the eGFP or hNIS lentivirus in 293T cells
The day before the transfection, 4 Â 10 6 of 293T cells were plated in 10 cm culture dish in DMEM proliferation medium supplemented with 10% of FBS. Cells were then transfected with the 15 mg of CMV-hNIS-Ires-Neo vector using the PEI transfection reagent to produce the human sodium iodide symporter (hNIS) lentivirus. As a control, 293T cells were transfected with the 15 mg of pCMVeGFP. In both cases, cells were cotransfected with 6.5 mg of GP, 3.5 mg of VSVG and 2.5 mg of REV plasmids to permit the production of the lentivirus. Cells were incubated overnight in a serum-free proliferation medium. The day after the transfection, cells were washed once with HBSS and fresh DMEM supplemented with FBS was added to each dish. Produced hNIS lentivirus and eGFP lentivirus were collected from transfected 293T cells 48, 72 and 96 h after the transfection. The lentivirus was then frozen in liquid nitrogen and stored at À80 1C until the infection.
Myoblast infection with hNIS and eGFP lentivirus
Human myoblasts were infected with lentivirus expressing either eGFP or hNIS. The day before the infection, cells were plated into 6-well plates. Cells were transduced with pCMV-eGFP or CMV-hNIS-Ires-Neo particles in presence of 6 mg per ml of polybren. Cells were washed twice with PBS 16 h after transduction to remove all viral particles. All cells were then cultured for 1 week. During the culture, cells were transferred in T-75 flasks. hNIS positive cells were then selected by culturing them in a growth medium supplemented with 500 ng ml À1 neomycin.
In vivo quantification of myoblast engraftment by g-radiographs as previously reported Human myoblasts were infected with a CMV-hNIS-IresNeo vector to make them express the hNIS. The neomycin-resistant myoblasts were then selected and transplanted in TA muscles of SCID mice electroporated either with the vector coding for VEGF 165 or with an empty vector. Intraperitoneal injections of Na 99 mTcO 4 permitted to quantify its uptake within the transplanted myoblasts or myofibers that they had formed using g-camera. This technique was used to assess repetitively in vivo the myoblast engraftment (survival and proliferation) at different times. 42 
Statistical analysis
Differences among groups were statistically analyzed using analysis of variance test. A value of Po0.05 was considered significant. Data are represented as means ± s.d.
